The acquisition of Mead Johnson Nutrition is a significant step forward in consumer health for RB in a structurally attractive category
It aligns with RB’s well established strategic focus on growing in consumer health and on investing in Powerbrands with attractive growth prospects. RB already reaches millions of mothers through its hygiene education programmes and, through world class brands such as Nurofen and Mucinex, provides parents with relief and reassurance when their children are unwell. This will be enhanced by Mead Johnson’s deep understanding of infant nutrition and a new mother’s journey.
Mead Johnson, a global leader in infant and children’s nutrition, develops, manufactures, markets and distributes more than 70 products in over 50 markets worldwide. The company’s mission is to nourish the world’s children for the best start in life.
The Mead Johnson name has been associated with science-based infant and children’s nutrition products for over 100 years. The company’s Enfa family of brands, including Enfamil infant formula, is the world’s leading franchise in infant and children’s nutrition.
In the year ended 31 December 2016, Mead Johnson reported net sales of $3,743 million, of which 50% were generated in Asia, 17% in Latin America and 33% in North America / Europe. On a US GAAP basis, Mead Johnson reported earnings before interest and income taxes of $819 million, earnings before income taxes of $713 million and net earnings attributable to shareholders of $545 million. On a non-US GAAP basis, Mead Johnson reported earnings before interest and income taxes of $927 million and EBITDA of $1,026 million. As at 31 December 2016, Mead Johnson reported total assets of $4,088 million.